- In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member
- Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as the company
- Fibromyalgia affects millions globally, but existing approved treatments have limited efficacy and/or cause significant side effects
- Tryp aims to remedy this, alleviating the suffering of millions of patients
In February of 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company, appointed Dr. Robin Carhart-Harris to its Scientific Advisory Board (“SAB”) (https://ibn.fm/jSASb). The founder of the first-of-its-kind Center for Psychedelic Research at Imperial College London and the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco, Dr. Carhart-Harris continues to be instrumental in advising Tryp through the development of its psilocybin programs.
In July, (https://ibn.fm/NkpfQ), Tryp also appointed Dr. Daniel Clauw, M.D. as a new member of the board. A Professor of anesthesiology, medicine (Rheumatology), and psychiatry at the University of Michigan, Dr. Clauw serves as the Director of the university’s Chronic Pain and Fatigue Research Center. He is also a world-renowned expert on fibromyalgia and nociplastic pain.
“I would like to thank Dr. Robin Carhart-Harris and Dr. Daniel Clauw for their persistent commitment not only to Tryp but also to the alleviation of chronic pain and other diseases with psychedelic-based therapies,” said Tryp Chairman and CEO Greg McKee following the July appointments.
Dr. Clauw’s commitment and work are captured in a 2020 Scientific American article titled “The Unexpected Diversity of Pain” (https://ibn.fm/NNuXh). The article, which discusses three types of pain (nociceptive, neuropathic, and nociplastic), noted that Dr. Clauw is passionate about helping people with nociplastic pain, a kind of long-misunderstood pain that could underpin chronic conditions, including fibromyalgia.
According to the article, nociplastic pain “results from no obvious inflammation or injury. Rather, it’s as if the volume knob for pain is turned up way too high, not at the pain site itself but further afield.” This type of pain appears to originate in parts of the central nervous system – the brain or spinal cord – that receive, transmit, or process pain signals.
“These nerves misfire, creating a sensation of pain even though nothing may be wrong. The localization of the problem, the central nervous system, is why Clauw prefers to call it ‘central sensitization.’ The classic example is fibromyalgia, which causes pain that seems to stem from muscles, tendons, and joints, despite the real problem lying in the brain or spinal cord,” explained the article.
According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people) (https://ibn.fm/AR0oK). Unfortunately, despite the disease afflicting millions, researchers have not yet made substantial gains in treating fibromyalgia at its origin. Existing FDA approved treatments, for example, have limited efficacy and/or significant side effects. Tryp is looking to change this narrative.
Through the guidance of its SAB, which also includes Joel Castellanos, M.D., Rachel Wervick, Ph.D., Derek Ott, M.D., and William Schmidt, Ph.D., coupled with research-based work conducted in collaboration with the University of Michigan, Tryp hopes to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients.
To this end, Tryp recently announced that it expects to file a separate Investigational Drug (“IND”) application before the end of October for its Phase 2a study in fibromyalgia through a collaboration with the University of Michigan (https://ibn.fm/jweV9).
Having already received IND authorization for a Phase 2a clinical trial in phantom limb pain, Tryp is moving forward with the academic collaboration for this condition. In addition, the company is continuing to advance the partnership for a Phase 2a clinical trial in complex regional pain syndrome.
Meanwhile, Tryp announced that the FDA had placed a clinical hold on its Phase 2a study for eating disorders, including binge eating disorder and hypothalamic obesity.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.